Tiziana Life Sciences Ltd (NASDAQ:TLSA – Get Free Report) CEO Ivor Elrifi acquired 667,000 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were bought at an average price of $1.00 per share, for a total transaction of $667,000.00. Following the acquisition, the chief executive officer directly owned 4,472,261 shares of the company’s stock, valued at approximately $4,472,261. This trade represents a 17.53% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.
Tiziana Life Sciences Price Performance
TLSA stock opened at $0.99 on Thursday. The company’s 50-day moving average is $1.15 and its 200-day moving average is $1.30. Tiziana Life Sciences Ltd has a 1 year low of $0.87 and a 1 year high of $2.53.
Institutional Investors Weigh In On Tiziana Life Sciences
Institutional investors and hedge funds have recently made changes to their positions in the business. Zhang Financial LLC lifted its position in Tiziana Life Sciences by 12.0% in the 1st quarter. Zhang Financial LLC now owns 111,900 shares of the company’s stock valued at $131,000 after acquiring an additional 12,000 shares in the last quarter. OMERS ADMINISTRATION Corp bought a new stake in Tiziana Life Sciences during the 4th quarter worth approximately $59,000. Marshall Wace LLP increased its holdings in Tiziana Life Sciences by 5.2% during the 4th quarter. Marshall Wace LLP now owns 282,017 shares of the company’s stock worth $420,000 after purchasing an additional 14,005 shares in the last quarter. HRT Financial LP purchased a new stake in shares of Tiziana Life Sciences in the fourth quarter worth approximately $36,000. Finally, Goldman Sachs Group Inc. raised its stake in shares of Tiziana Life Sciences by 413.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 110,290 shares of the company’s stock worth $164,000 after purchasing an additional 88,830 shares during the last quarter.
Analysts Set New Price Targets
View Our Latest Research Report on TLSA
About Tiziana Life Sciences
Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.
The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.
Featured Stories
- Five stocks we like better than Tiziana Life Sciences
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
